Drug Discovery & Development reports that biotech is heating up ahead of ASCO 2026, with the field shifting focus beyond PD-1 inhibitors toward next-generation cancer therapies. The SPDR S&P Biotech ETF (XBI) has gained roughly 69% over the past year, signaling strong investor appetite for emerging oncology platforms.
Global life sciences M&A reached $240 billion in 2025 — an 81% jump from the prior year — with EY reporting a record $2.1 trillion in deal capacity. Goldman Sachs expects broader M&A volume to rise sharply, though the article does not detail which specific drug classes or trial results will be featured at ASCO.
The surge in dealmaking suggests large pharma is aggressively scouting novel mechanisms, including bispecific antibodies, antibody-drug conjugates, and cell therapies, to replace maturing PD-1 franchises. However, no specific clinical data, regulatory filings, or patient outcomes are provided in this preview.
Investor enthusiasm has lifted the XBI significantly, but the article lacks concrete pipeline milestones or efficacy numbers. The biotech rally may be driven more by M&A speculation than by near-term clinical catalysts.
A key caveat: the piece is a forward-looking market overview rather than a data-driven clinical update, and no specific drug names or company mentions appear in the source. Actual ASCO abstracts will determine whether the pipeline can justify current valuations.